CN107698684B - GLP-1 fusion proteins comprising a mutated immunoglobulin Fc portion - Google Patents
GLP-1 fusion proteins comprising a mutated immunoglobulin Fc portion Download PDFInfo
- Publication number
- CN107698684B CN107698684B CN201710630742.6A CN201710630742A CN107698684B CN 107698684 B CN107698684 B CN 107698684B CN 201710630742 A CN201710630742 A CN 201710630742A CN 107698684 B CN107698684 B CN 107698684B
- Authority
- CN
- China
- Prior art keywords
- ser
- val
- glu
- pro
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title claims abstract description 87
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 83
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 79
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 35
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 35
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title claims abstract 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 23
- 238000006467 substitution reaction Methods 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 208000008589 Obesity Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 239000000710 homodimer Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 15
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 70
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 61
- 235000001014 amino acid Nutrition 0.000 description 48
- 229940024606 amino acid Drugs 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 30
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 25
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 19
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 19
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000035772 mutation Effects 0.000 description 12
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 11
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 10
- HAPWZEVRQYGLSG-IUCAKERBSA-N His-Gly-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O HAPWZEVRQYGLSG-IUCAKERBSA-N 0.000 description 10
- IVDFVBVIVLJJHR-LKXGYXEUSA-N Thr-Ser-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IVDFVBVIVLJJHR-LKXGYXEUSA-N 0.000 description 10
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 10
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 108010045383 histidyl-glycyl-glutamic acid Proteins 0.000 description 10
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 9
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 9
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 9
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 description 9
- NYGILGUOUOXGMJ-YUMQZZPRSA-N Asn-Lys-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O NYGILGUOUOXGMJ-YUMQZZPRSA-N 0.000 description 9
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 9
- KBQOUDLMWYWXNP-YDHLFZDLSA-N Asn-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KBQOUDLMWYWXNP-YDHLFZDLSA-N 0.000 description 9
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 9
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 9
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 9
- SMEYEQDCCBHTEF-FXQIFTODSA-N Cys-Pro-Ala Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O SMEYEQDCCBHTEF-FXQIFTODSA-N 0.000 description 9
- KSMSFCBQBQPFAD-GUBZILKMSA-N Cys-Pro-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 KSMSFCBQBQPFAD-GUBZILKMSA-N 0.000 description 9
- ALTQTAKGRFLRLR-GUBZILKMSA-N Cys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N ALTQTAKGRFLRLR-GUBZILKMSA-N 0.000 description 9
- 108091006020 Fc-tagged proteins Proteins 0.000 description 9
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 description 9
- CGVWDTRDPLOMHZ-FXQIFTODSA-N Gln-Glu-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O CGVWDTRDPLOMHZ-FXQIFTODSA-N 0.000 description 9
- KCJJFESQRXGTGC-BQBZGAKWSA-N Gln-Glu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O KCJJFESQRXGTGC-BQBZGAKWSA-N 0.000 description 9
- AQPZYBSRDRZBAG-AVGNSLFASA-N Gln-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N AQPZYBSRDRZBAG-AVGNSLFASA-N 0.000 description 9
- HMIXCETWRYDVMO-GUBZILKMSA-N Gln-Pro-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O HMIXCETWRYDVMO-GUBZILKMSA-N 0.000 description 9
- RFDHKPSHTXZKLL-IHRRRGAJSA-N Glu-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N RFDHKPSHTXZKLL-IHRRRGAJSA-N 0.000 description 9
- YHOJJFFTSMWVGR-HJGDQZAQSA-N Glu-Met-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YHOJJFFTSMWVGR-HJGDQZAQSA-N 0.000 description 9
- AAJHGGDRKHYSDH-GUBZILKMSA-N Glu-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O AAJHGGDRKHYSDH-GUBZILKMSA-N 0.000 description 9
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 9
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 9
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 9
- OOCFXNOVSLSHAB-IUCAKERBSA-N Gly-Pro-Pro Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OOCFXNOVSLSHAB-IUCAKERBSA-N 0.000 description 9
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 9
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 9
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 9
- WZPIKDWQVRTATP-SYWGBEHUSA-N Ile-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 WZPIKDWQVRTATP-SYWGBEHUSA-N 0.000 description 9
- DFJJAVZIHDFOGQ-MNXVOIDGSA-N Ile-Glu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N DFJJAVZIHDFOGQ-MNXVOIDGSA-N 0.000 description 9
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 9
- 241000880493 Leptailurus serval Species 0.000 description 9
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 description 9
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 9
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 9
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 9
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 9
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 9
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 9
- DUTMKEAPLLUGNO-JYJNAYRXSA-N Lys-Glu-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DUTMKEAPLLUGNO-JYJNAYRXSA-N 0.000 description 9
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 9
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 9
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 9
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 9
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 9
- LHALYDBUDCWMDY-CIUDSAMLSA-N Pro-Glu-Ala Chemical compound C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O LHALYDBUDCWMDY-CIUDSAMLSA-N 0.000 description 9
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 9
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 9
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 9
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 description 9
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 9
- HZWAHWQZPSXNCB-BPUTZDHNSA-N Ser-Arg-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HZWAHWQZPSXNCB-BPUTZDHNSA-N 0.000 description 9
- VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 description 9
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 9
- MOVJSUIKUNCVMG-ZLUOBGJFSA-N Ser-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)O MOVJSUIKUNCVMG-ZLUOBGJFSA-N 0.000 description 9
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 9
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 9
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 9
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 9
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 9
- QJKPECIAWNNKIT-KKUMJFAQSA-N Ser-Lys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QJKPECIAWNNKIT-KKUMJFAQSA-N 0.000 description 9
- HNDMFDBQXYZSRM-IHRRRGAJSA-N Ser-Val-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HNDMFDBQXYZSRM-IHRRRGAJSA-N 0.000 description 9
- LAFLAXHTDVNVEL-WDCWCFNPSA-N Thr-Gln-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O LAFLAXHTDVNVEL-WDCWCFNPSA-N 0.000 description 9
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 9
- SSSDKJMQMZTMJP-BVSLBCMMSA-N Trp-Tyr-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 SSSDKJMQMZTMJP-BVSLBCMMSA-N 0.000 description 9
- GZUIDWDVMWZSMI-KKUMJFAQSA-N Tyr-Lys-Cys Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GZUIDWDVMWZSMI-KKUMJFAQSA-N 0.000 description 9
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 9
- SCBITHMBEJNRHC-LSJOCFKGSA-N Val-Asp-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N SCBITHMBEJNRHC-LSJOCFKGSA-N 0.000 description 9
- OACSGBOREVRSME-NHCYSSNCSA-N Val-His-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(O)=O OACSGBOREVRSME-NHCYSSNCSA-N 0.000 description 9
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 9
- 108010005233 alanylglutamic acid Proteins 0.000 description 9
- 108010087924 alanylproline Proteins 0.000 description 9
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 9
- 108010047857 aspartylglycine Proteins 0.000 description 9
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 9
- 108010049041 glutamylalanine Proteins 0.000 description 9
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 9
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 9
- 108010010147 glycylglutamine Proteins 0.000 description 9
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 9
- 108010064235 lysylglycine Proteins 0.000 description 9
- 108010073101 phenylalanylleucine Proteins 0.000 description 9
- 108010051242 phenylalanylserine Proteins 0.000 description 9
- 108010077112 prolyl-proline Proteins 0.000 description 9
- 108010031719 prolyl-serine Proteins 0.000 description 9
- 108010070643 prolylglutamic acid Proteins 0.000 description 9
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 9
- 108010080629 tryptophan-leucine Proteins 0.000 description 9
- 108010051110 tyrosyl-lysine Proteins 0.000 description 9
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 9
- YUELDQUPTAYEGM-XIRDDKMYSA-N Asp-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)O)N YUELDQUPTAYEGM-XIRDDKMYSA-N 0.000 description 8
- BPCLDCNZBUYGOD-BPUTZDHNSA-N Glu-Trp-Glu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 BPCLDCNZBUYGOD-BPUTZDHNSA-N 0.000 description 8
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 8
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 8
- BKTXKJMNTSMJDQ-AVGNSLFASA-N Leu-His-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BKTXKJMNTSMJDQ-AVGNSLFASA-N 0.000 description 8
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 8
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 8
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 108010011459 Exenatide Proteins 0.000 description 7
- RKIIYGUHIQJCBW-SRVKXCTJSA-N Met-His-Glu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RKIIYGUHIQJCBW-SRVKXCTJSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960001519 exenatide Drugs 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000002741 site-directed mutagenesis Methods 0.000 description 7
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 6
- 108010019598 Liraglutide Proteins 0.000 description 6
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 6
- 229960002701 liraglutide Drugs 0.000 description 6
- HPSVTWMFWCHKFN-GARJFASQSA-N Arg-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O HPSVTWMFWCHKFN-GARJFASQSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- LBFXVAXPDOBRKU-LKTVYLICSA-N Ala-His-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LBFXVAXPDOBRKU-LKTVYLICSA-N 0.000 description 4
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 4
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 4
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 4
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 4
- FWAHLGXNBLWIKB-NAKRPEOUSA-N Met-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCSC FWAHLGXNBLWIKB-NAKRPEOUSA-N 0.000 description 4
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 108010005794 dulaglutide Proteins 0.000 description 4
- 229960005175 dulaglutide Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000004665 fatty acids Chemical group 0.000 description 4
- 108010040030 histidinoalanine Proteins 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229960001093 lixisenatide Drugs 0.000 description 4
- 108010004367 lixisenatide Proteins 0.000 description 4
- 108700027806 rGLP-1 Proteins 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 102200069889 rs104893964 Human genes 0.000 description 4
- 102200077973 rs113068438 Human genes 0.000 description 4
- 102220074722 rs796053167 Human genes 0.000 description 4
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- WQLJRNRLHWJIRW-KKUMJFAQSA-N Asn-His-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)N)N)O WQLJRNRLHWJIRW-KKUMJFAQSA-N 0.000 description 3
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 3
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 3
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 3
- 102400000324 Glucagon-like peptide 1(7-37) Human genes 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- QARCDOCCDOLJSF-HJPIBITLSA-N Tyr-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QARCDOCCDOLJSF-HJPIBITLSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 229960004733 albiglutide Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940081330 tena Drugs 0.000 description 3
- OPDFUQJBZZJZRG-WPJYNPJPSA-N (4r,4as,7r,7ar,12bs)-7-[2-[2-[2-[[(4r,4as,7r,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-yl]amino]ethoxy]ethoxy]ethylamino]-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-me Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC[C@H]5NCCOCCOCCN[C@H]2[C@@H]3OC=4C(O)=CC=C5C[C@@H]6[C@]([C@@]3(CCN6CC3CC3)C5=4)(O)CC2)O)CC1)O)CC1CC1 OPDFUQJBZZJZRG-WPJYNPJPSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 2
- KXODZBLFVFSLAI-AVGNSLFASA-N Leu-His-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CN=CN1 KXODZBLFVFSLAI-AVGNSLFASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 2
- WEQAYODCJHZSJZ-KKUMJFAQSA-N Ser-His-Tyr Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 WEQAYODCJHZSJZ-KKUMJFAQSA-N 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- BXPOOVDVGWEXDU-WZLNRYEVSA-N Tyr-Ile-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BXPOOVDVGWEXDU-WZLNRYEVSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229930188854 dolastatin Natural products 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- -1 hexadecanoic acid modified glutamine Chemical class 0.000 description 2
- 108010036413 histidylglycine Proteins 0.000 description 2
- 108010018006 histidylserine Proteins 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003509 long acting drug Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 108010060325 semaglutide Proteins 0.000 description 2
- 229950011186 semaglutide Drugs 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- PXAFZDXYEIIUTF-LKTVYLICSA-N Ala-Trp-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O PXAFZDXYEIIUTF-LKTVYLICSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000003626 gastrointestinal polypeptide Substances 0.000 description 1
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
The present invention relates to fusion proteins comprising GLP-1 or an analog thereof, a peptide linker and a mutated immunoglobulin Fc part, which have an increased half-life. The invention also provides a method for producing the fusion protein and application of the fusion protein in preparing medicines.
Description
Technical Field
The present invention relates to a fusion protein of glucagon-like peptide-1 (GLP-1), comprising a mutated immunoglobulin Fc part, thus having an extended half-life in vivo. The fusion protein can be used for treating diabetes, obesity and other related diseases or disorders.
Background
Glucagon-like peptide-1 (GLP-1) is originally separated and extracted from intestinal mucosa, is a gastrointestinal peptide secreted by ileum endocrine cells, and is mainly used as a target of medicament action of type 2 diabetes at present. GLP-1 can inhibit gastric emptying and reduce intestinal peristalsis, so that it is helpful for controlling food intake and reducing body weight.
GLP-1 produced in the intestinal tract initially is 37 peptide which is an inactive peptide chain, the N-terminal 6 peptide needs to be removed by enzymolysis to form GLP-1(7-37) with biological activity, and the C-terminal glycine of the GLP-1 can be used as a substrate of amidation enzyme, so that about 80 percent of GLP-1 naturally produced in the intestinal tract is GLP-1(7-36) amide, and the sequence of the GLP-1 is the same in mammals which are researched at present. C-terminal amidation increases the in vivo stability of GLP-1.
The amino acid sequence of the natural GLP-1(7-37) is as follows:
HisAlaGluGlyThrPheThrSerAspValSerSerTyrLeuGluGlyGlnAlaAlaLysGluPheIleAlaTrpLeuValLysGlyArgGly
GLP-1 has an N-terminal and a C-terminal, wherein the N-terminal is related to the physiological activity of the GLP-1, and the C-terminal is related to the binding of a receptor. Dipeptidyl peptidase IV (DPP IV) can catalyze and hydrolyze 2 nd alanine at N end of GLP-1 to form GLP-1 (9-36) NH2Lose activity and are natural antagonists of GLP-1R in vivo. GLP-1 has short biological half-life of 1-1.5 min and is quickly degraded by dipeptidase IV, so that the concentration of the GLP-1 in blood is difficult to detect clinically. Therefore, structural modification of GLP-1 to form GLP-1 analogues with the same pharmacological activity, covering the binding site of DPP-IV and prolonging half-life are main subjects of development of the medicaments.
In the last years, Novonide, GSK and the like compete to modify the protein so as to obtain the long-acting GLP-1 hypoglycemic drug.
Exenatide (exenatide) is a bioactive peptide extracted from the salivary gland of lizard, and the amino acid sequence of the exenatide is 53% homologous with GLP-1. Studies have shown that the dosing period can be extended to twice daily. The amino acid sequence of exenatide is as follows:
H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
as the second position of the N end of the GLP-1 is replaced by Gly in the GLP-1, the DPP-IV can not degrade the GLP-1, and the GLP-IV has longer half-life and stronger biological activity.
Liraglutide (liraglutide) is a drug for modifying the fatty acid chain of GLP-1 protein, and the administration period is prolonged to once a day. The liraglutide is characterized in that 34-position Lys of a GLP-1(7-37) chain is replaced by Arg, and the 26-position Lys is connected with hexadecanoic acid modified glutamine. After GLP-1 is modified by the fatty chain, the affinity between the GLP-1 and albumin is increased, so that the hydrolysis rate and renal clearance of DPP-IV are reduced, and the biological half-life is prolonged.
The peptide Lixinaside (trade name: lyxumia) was co-developed by Sanofi Aventis and Zealand, France. The amino acid sequence of the linatide is shown below:
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2
structurally, the risperidone is Exendin-4 with the 38 th Pro removed and the 39 th Ser linked to 6 Lys. Through structural modification, the half-life of Lixisenatide is prolonged compared with that of Exenaatide, and the Lixisenatide can be subcutaneously injected once a day.
Abbiglutide (Albiglite) (trade name: Eperzan) is a weekly subcutaneous injection of long-acting GLP-1 analogs developed by GlaxoSmithKline. Structurally, Albiglutamide is obtained by replacing Ala at position 8 of GLP-1(7-36) chain with Gly, and fusing two modified GLP-1 peptide chains in tandem on serum albumin containing 585 residues, thus greatly prolonging half-life.
Dolaglutide (Dulaglutide) is a weekly subcutaneous long acting GLP-1 analogue developed by Lily corporation. Structurally, Dulaglutide has an average biological half-life of 90 hours, wherein Ala at position 8 in GLP-1(7-37) chain is replaced by Gly, Gly at position 22 is replaced by Glu, Arg at position 36 is replaced by Gly, and the Dulaglutide is fused to glutamic acid at position 216 in recombinant IgG4 immune albumin (containing 227 amino acid Fc fragment) through an GGGGSGGGGSGGGGSA coupling bridge.
Somaglutide (semaglutide) is a long-acting GLP-1 analogue developed by Nove Nordisk corporation that is injected subcutaneously once a week. In structural view, Semeglitide is formed by replacing Ala at position 8 in GLP-1(7-37) chain with Aib, Lys at position 34 with Arg, and Lys at position 26 with octadecanoic acid fatty chain. Compared with liraglutide, the fat chain of the soxhlet peptide is longer, the hydrophobicity is increased, but the hydrophilicity of the soxhlet peptide is greatly enhanced through short-chain PEG modification. After being modified by PEG, the modified PEG not only can be tightly combined with albumin to cover DPP-4 enzyme hydrolysis sites, but also can reduce renal excretion, prolong half-life and achieve the effect of long circulation.
The GLP-1 class of drugs which are the most long-acting drugs on the market at present have the injection frequency of once per week. The long-acting GLP-1 medicament with better action time is developed, so that frequent medicament injection is reduced, and the compliance of patients is improved.
Disclosure of Invention
In one aspect of the invention, there is provided a fusion protein comprising or consisting of: GLP-1 or an analog thereof; a peptide linker; and an immunoglobulin Fc portion, wherein amino acid N of the immunoglobulin Fc portion at position 434 (numbered according to the EU numbering system) is replaced with a weakly hydrophobic amino acid, wherein the hydrophobic amino acid is selected from the group consisting of alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, and methionine, preferably alanine. Thereby having an increased half-life in an animal, preferably a mammal, such as a mouse, more preferably a human.
In one embodiment of the fusion protein of the invention, the C-terminus of the GLP-1 or analog thereof is fused to the N-terminus of the Fc moiety via the peptide linker, and/or wherein the immunoglobulin Fc moiety is from human IgG1, IgG2, IgG3 or IgG 4.
In another embodiment of the fusion protein of the invention, the immunoglobulin Fc portion further comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) amino acid substitutions (numbered according to the EU numbering system) selected from the group consisting of: S228P, F234A, L235A, M252Y, T256E, T307A, E380A and M428L, preferably comprising S228P, F234A, L235A and optionally one or more (e.g. 1, 2, 3, 4 or 5) amino acid substitutions (numbering according to the EU numbering system) selected from the group consisting of: M252Y, T256E, T307A, E380A and M428L, more preferably comprising S228P, F234A, L235A and optionally one or more (e.g. 1, 2, 3, 4 or 5) amino acid substitutions (numbering according to the EU numbering system) selected from the group consisting of: T307A, E380A and M428L.
In another embodiment of the fusion protein of the invention, the immunoglobulin Fc portion comprises a combination of amino acid substitutions (numbered according to the EU numbering system) selected from the group consisting of:
1)S228P+F234A+L235A+N434A；
2)S228P+F234A+L235A+M428L+N434A；
3) S228P + F234A + L235A + T307A + E380A + N434A; and
4)S228P+F234A+L235A+M252Y+T256E+N434A。
in another embodiment of the fusion protein of the invention, the fusion protein has one or more characteristics selected from the group consisting of:
1) said GLP-1 or analog thereof has one or more (2 or 3) amino acid substitutions (numbered according to the EU numbering system) selected from the group consisting of: A8G, G22E and R36G;
2) the GLP-1 or analog thereof has a (C) over 1-5 (e.g., 1, 2, 3, 4, or 5) amino acid residues12-24E.g. C12、C14、C16Or C18Long chain) fatty acid modification; and
3) the amino acid 27 of the GLP-1 or analog portion thereof and the amino acid 216 of the immunoglobulin Fc portion (numbered according to the EU numbering system) of the fusion protein are both negatively charged, while the amino acid 34 of the GLP-1 or analog portion thereof and the amino acid 218 of the immunoglobulin Fc portion (numbered according to the EU numbering system) are both positively charged, and GLP-1 or analog thereof comprises a contiguous stretch of polar amino acid residues (of 10-30 amino acid residues) intermediate to the immunoglobulin Fc portion.
In another embodiment of the fusion protein of the invention, the amino acid sequence of the fusion protein is selected from the group consisting of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 and SEQ ID No. 4; and/or wherein the amino acid sequence of the GLP-1 or the analogue thereof is shown as SEQ ID NO. 6; and/or wherein the amino acid sequence of the peptide linker is shown as SEQ ID No. 7.
In another embodiment of the fusion protein of the invention, the fusion protein is present in dimeric form, preferably in homodimeric form.
In another aspect of the invention, polynucleotides are provided which encode the fusion proteins of the invention.
In another aspect of the invention, there is also provided a vector comprising a polynucleotide according to the invention.
In another aspect of the invention, there is also provided a host cell comprising a vector according to the invention, preferably the host cell is a CHO cell.
In another aspect of the invention, there is also provided a method of producing a fusion protein according to the invention, said method comprising expressing a vector according to the invention in a host cell.
In another aspect of the invention there is also provided the use of a fusion protein of the invention in the manufacture of a medicament, preferably for the treatment of diabetes or obesity.
Drawings
FIG. 1 is a schematic representation of a GLP-1 fusion protein of the invention comprising a mutated immunoglobulin Fc part (left to right: N-terminal to C-terminal);
FIG. 2. amino acid sequence of fusion protein (Na) comprising Fc mutant 1 (SEQ ID NO. 1);
FIG. 3 amino acid sequence of fusion protein (MNa) comprising Fc mutant 2 (SEQ ID NO. 2);
FIG. 4 amino acid sequence of fusion protein (TENA) comprising Fc mutant 3 (SEQ ID NO. 3);
FIG. 5 amino acid sequence of fusion protein (MTNa) comprising Fc mutant 4 (SEQ ID NO. 4);
FIG. 6. the amino acid sequence of dolastatin (SEQ ID NO. 5);
FIG. 7 is the amino acid sequence of YES (S228P, F234A, L235A, M252Y, T256E, N434S) (SEQ ID NO. 8);
FIG. 8 amino acid sequence of YTE (S228P, F234A, L235A, M252Y, S254T, T256E) (SEQ ID NO. 9);
FIG. 9 amino acid sequence of YTELS (S228P, F234A, L235A, M252Y, S254T, T256E, M428L, N434S) (SEQ ID NO. 10);
FIG. 10. the amino acid sequence of YE (S228P, F234A, L235A, M252Y, T256E) (SEQ ID NO. 11);
FIG. 11 in vitro activity assay of fusion proteins of the invention; and
FIG. 12 is a schematic representation of the design of homodimeric fusion proteins according to an embodiment of the invention, wherein the Fc fusion protein comprises an antibody Fc region and a unique drug fusion fragment (GLP-1 or analog thereof) comprising a flexible region of about 5nm, both the E27 site of the GLP-1 protein and the E216 site of the Fc protein (numbered according to the EU numbering system) are negatively charged, and both the K34 site of the GLP-1 protein and the K218 site of the Fc protein (numbered according to the EU numbering system) are positively charged, the structure being such that the drug fusion fragment of about 5nm in length potentially interacts with the charged and polar residues present on the Fc fragment, further affecting the steric status of the drug fragment.
Detailed Description
The Fc fusion protein medicine is a new functional recombinant protein obtained by fusing functional protein and immunoglobulin Fc fragment by utilizing the techniques of gene engineering and the like. Fc fusion proteins and antibodies belong to different types of proteins. The essential differences are as follows: the antibody comprises two heavy chains and two light chains, and the Fc fragment is positioned in the constant region of the heavy chains; and Fc fusion proteins include functional proteins and Fc fragments. This feature of Fc fusion proteins also allows them to retain the biological activity of functional proteins and also have the properties of antibodies such as long-lasting half-life.
The long-acting drug with obvious advantages in the half-life of the drug is obtained by carrying out structural modification on the Fc region of the Fc fusion protein.
More specifically, the present invention provides a GLP-1 Fc fusion protein with long-lasting hypoglycemic capacity, which is obtained by connecting a GLP-1 analogue and an Fc mutant through a peptide, wherein the Fc mutant has at least one mutation: amino acid N434 is substituted with a434 (numbering according to the EU index).
According to a specific embodiment of the present invention, there is provided a fusion protein comprising or consisting of: GLP-1 or an analog thereof; a peptide linker; and an immunoglobulin Fc portion, wherein amino acid N of the immunoglobulin Fc portion at position 434 (numbered according to the EU numbering system) is replaced with a weakly hydrophobic amino acid, preferably the immunoglobulin Fc portion comprises amino acid substitution N434A (numbered according to the EU numbering system) (note: herein, the amino acid substitution of the immunoglobulin Fc portion uses the nomenclature: initial amino acid, position (numbered according to the EU numbering system), replacement amino acid.
Native GLP-1 is processed in vivo with the first 6 amino acids cleaved off, so the art commonly designates the amino terminus (N-terminus) of GLP-1 as position 7 and the carboxy terminus (C-terminus) as position 37.
Other GLP-1 analogs that retain the native biological activity of GLP-1 are known to those skilled in the art or can be determined by routine experimentation.
Preferably, the GLP-1 analogs described in the present invention comprise 1-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid substitutions (e.g., conservative amino acid substitutions), deletions, or insertions in the native GLP-1 sequence, thereby extending the in vivo half-life of GLP-1 and, at the same time, retaining the native biological activity of GLP-1. Preferably, GLP-1 analogues as disclosed for example in CN1802386A, in particular SEQ ID NOs.1-6 as disclosed in CN 1802386A.
Preferably, GLP-1 analogs described in the invention comprise a (C) at 1-5 (e.g., 1, 2, 3, 4, or 5) amino acid residues of the native GLP-1 sequence12-24E.g. C12、C14、C16Or C18Long chain) fatty acid modification, thereby extending half-life in vivo.
In a preferred embodiment of the invention, the GLP-1 analogue described in the present invention is selected from the group consisting of Exenatide (Exenatide), Liraglutide (Liraglutide), lissamide (Lixisenatide), Albiglutide (Albiglutide), dolaglutide (Dulaglutide) and somaglutide (semaglutide). Wherein said Albiglutide and dolaglutide refer to the GLP-1 moiety in their structures.
A representative sequence of GLP-1 analogs described in this invention (left to right: N-terminal to C-terminal) is shown below:
HisGly8GluGlyThrPheThrSerAspValSerSerTyrLeuGluGlu22GlnAlaAlaLysGlu PheIleAlaTrpLeuValLysGlyGly36Gly(SEQ ID NO:6)
compared with the natural GLP-1(7-37) in the human body, three amino acids are replaced: A8G, G22E, R36G, with the aim of reducing degradation of the analogue by endogenous enzymes, reducing the potential for molecular aggregation and/or reducing immunogenicity. In this sequence, amino acid E27 at position 27 is negatively charged, while amino acid K34 at position 34 is positively charged. The distribution of these residues exhibits the characteristic charge distribution characteristic of GLP-1 active protein residues.
The GLP-1 fusion protein disclosed by the invention has the following characteristics: amino acid 27 of GLP-1 protein (e.g., E27) and amino acid 216 of immunoglobulin Fc (numbered according to the EU numbering system, e.g., E216) have negative charges, while amino acid 34 of GLP-1 protein (e.g., K34) and amino acid 218 of immunoglobulin Fc (numbered according to the EU numbering system, e.g., K218) have positive charges, and a continuous segment of polar residues (e.g., GGGGSGGGGSGGGGS) is intermediate between GLP-1 protein and immunoglobulin Fc.
The peptide linker in the fusion protein of the invention may be selected from those well known in the art (e.g. the peptide linkers disclosed in CN1802386A, in particular SEQ ID nos.8,19 and 21 disclosed therein) as long as it does not adversely affect the activity of GLP-1 in the fusion protein and/or the stability of the fusion protein. The amino acid sequence of a representative preferred peptide linker for use in the fusion protein of the invention consists of (GGGGS) repeats plus a, representative sequences being:
GlyGlyGlyGlySerGlyGlyGlyGlySerGlyGlyGlyGlySerAla(SEQ ID NO:7)
according to a particular embodiment of the invention, the C-terminus of said GLP-1 or analog thereof is fused to the N-terminus of said Fc part via said peptide linker.
The Fc portion of the invention may be derived from human IgG1, IgG2, IgG3 or IgG 4.
Preferably, the Fc portion of the present invention is mutated to minimize effector function (e.g., L235A, F234A, numbered according to the EU numbering system, see Kabat, E.A. et al, (1991), Sequences of Proteins of Immunological Interest, fifth edition, U.S. Dept. of Health and Human Services, Bethesda, Md., NIH publication 91-3242). In addition, it is preferred that the Fc portion of the present invention is mutated (e.g., S228P) so as to be able to form a stable dimer structure.
After systematic modification and research are carried out on residues in an Fc section of the fusion protein, the inventor further discovers that mutation of the N434A site can obviously increase the drug half-life of GLP-1/Fc in blood, and is expected to develop a longer-acting GLP-1 hypoglycemic drug.
According to a particular embodiment of the invention, said immunoglobulin Fc portion in the fusion protein of the invention comprises, in addition to the N434A substitution, one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) amino acid substitutions (numbered according to the EU numbering system) selected from the group consisting of: S228P, F234A, L235A, M252Y, T256E, T307A, E380A and M428L, preferably comprising S228P, F234A, L235A and optionally further one or more (e.g. 1, 2, 3, 4 or 5) amino acid substitutions (numbering according to the EU numbering system) selected from the group consisting of: M252Y, T256E, T307A, E380A and M428L, more preferably comprising S228P, F234A, L235A and optionally one or more (e.g. 1, 2, 3, 4 or 5) amino acid substitutions (numbering according to the EU numbering system) selected from the group consisting of: T307A, E380A and M428L.
In a preferred embodiment of the invention, the immunoglobulin Fc part comprises a combination of amino acid substitutions (numbered according to the EU numbering system) selected from the group consisting of:
1)S228P+F234A+L235A+N434A；
2)S228P+F234A+L235A+M428L+N434A；
3) S228P + F234A + L235A + T307A + E380A + N434A; and
4)S228P+F234A+L235A+M252Y+T256E+N434A。
in a preferred embodiment of the invention, the fusion protein has one or more characteristics selected from the group consisting of:
1) said GLP-1 or analog thereof has one or more (2 or 3) amino acid substitutions (numbered according to the EU numbering system) selected from the group consisting of: A8G, G22E and R36G to improve the biological half-life of GLP-1 or an analog thereof;
2) the GLP-1 or analog thereof has (C12-24, such as C) at 1-5 (e.g., 1, 2, 3, 4, or 5) amino acid residues12、C14、C16Or C18Long chain) fatty acid modification to improve the biological half-life of GLP-1 or an analog thereof; and
3) amino acid 27 of the GLP-1 or analog portion thereof and amino acid 216 of the immunoglobulin Fc portion (numbered according to the EU numbering system) of the fusion protein are both negatively charged, while amino acid 34 of the GLP-1 or analog portion thereof and amino acid 218 of the immunoglobulin Fc portion (numbered according to the EU numbering system) are both positively charged, and a contiguous series of polar amino acid residues or a flexible fragment consisting essentially thereof (e.g., of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid residues) is contained between GLP-1 or analog thereof and the immunoglobulin Fc portion.
In a preferred embodiment of the invention, the fusion protein is present as a dimer; in a particularly preferred embodiment of the invention, the fusion protein is present as a homodimer.
In a particularly preferred embodiment of the invention, the amino acid sequence of the immunoglobulin Fc part is selected from the group consisting of SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO. 4; and/or wherein the amino acid sequence of the GLP-1 or the analogue thereof is shown as SEQ ID NO. 6; and/or wherein the amino acid sequence of the peptide linker is shown as SEQ ID No. 7.
The mutants of the immunoglobulin Fc part of the present invention can be prepared using any mutagenesis method known in the art, such as site-directed mutagenesis, synthetic gene construction, semi-synthetic gene construction, random mutagenesis, shuffling and the like.
Site-directed mutagenesis is a technique in which one or more (several) mutations are made at one or more restriction sites in a polynucleotide encoding a parent.
Site-directed mutagenesis can be accomplished in vitro by PCR involving the use of oligonucleotide primers containing the desired mutagenesis. Site-directed mutagenesis can also be performed in vitro by cassette mutagenesis involving cleavage of a restriction enzyme at a site in a plasmid comprising a polynucleotide encoding a parent and subsequent ligation of an oligonucleotide comprising the mutation in the polynucleotide. Restriction enzymes that digest the plasmid and oligonucleotide are typically identical, such that the cohesive ends of the plasmid and the insert are ligated to each other. Site-directed mutagenesis can also be accomplished in vivo by methods known in the art.
The present invention can use any site-directed mutagenesis procedure. There are many commercial kits available that can be used to prepare variants.
The mutagenesis/shuffling approach can be combined with a high throughput, automated screening method to detect the activity of cloned, mutagenized polypeptides expressed by host cells. Mutagenized DNA molecules encoding active polypeptides can be recovered from the host cells and rapidly sequenced using methods standard in the art. These methods allow for the rapid determination of the importance of individual amino acid residues in a polypeptide.
Semi-synthetic gene construction is accomplished by the combined use of synthetic gene construction, and/or site-directed mutagenesis, and/or random mutagenesis, and/or shuffling. Semi-synthetic construction is typically a combination of methods utilizing synthetic polynucleotide fragments and PCR techniques. Thus defined regions of the gene can be synthesized de novo, however other regions can be amplified using site-specific mutagenic primers, while other regions can be amplified by error-prone PCR or non-error-prone PCR. The polynucleotide subsequences may then be shuffled.
The invention also provides a polynucleotide encoding the fusion protein of the invention, a vector (particularly an expression vector) comprising the polynucleotide, and a host cell (preferably a CHO cell) which already comprises the vector. The terms "polynucleotide", "vector" and "host cell" have meanings well known in the art unless otherwise indicated.
The invention also provides a method of producing a fusion protein of the invention, the method comprising expressing a vector comprising a polynucleotide encoding a fusion protein of the invention in a host cell. The method can be performed according to recombinant protein expression methods known to those skilled in the art.
In addition, the invention also provides the use of the fusion protein of the invention for the preparation of a medicament, preferably for the treatment of diabetes or obesity.
The invention also relates to a pharmaceutical composition comprising a fusion protein of the invention, and optionally, at least one pharmaceutically acceptable carrier, diluent or excipient.
The invention also provides a method of treating diabetes or obesity comprising administering to a subject (e.g., a mammal, preferably any primate, but particularly a human) in need thereof a therapeutically effective amount of a fusion protein of the invention.
The invention is further described below by way of the following non-limiting experimental section and the accompanying drawings. Technical route summary:
1. designing a mutation site of an Fc part of immunoglobulin, and fusing a GLP-1 analogue with an IgG-Fc mutant through a peptide joint; the mutant fusion protein comprises three structural domains, as shown in figure 1, wherein GLP-1 is a GLP-1 active protein sequence, and the representative sequence is as follows:
HisGly8GluGlyThrPheThrSerAspValSerSerTyrLeuGluGlu22GlnAlaAlaLys GluPheIleAlaTrpLeuValLysGlyGly36Gly
compared with the natural GLP-1 active in the human body, three amino acids are replaced: A8G, G22E, R36G,
the peptide linker sequence consists of (GGGGS) repeats plus a, representing the sequence:
GlyGlyGlyGlySerGlyGlyGlyGlySerGlyGlyGlyGlySerAla
fc represents immunoglobulin Fc mutant.
The representative sequence of the mutant fusion protein is SEQ ID NOs.1-4, wherein:
the EU numbering of the Fc portion of SEQ ID No.1 is E216-G446, including the following amino acid substitutions: S228P, F234A, L235A, N434A;
the EU numbering of the Fc portion of SEQ ID No.2 is E216-G446, including the following amino acid substitutions: S228P, F234A, L235A, M428L, N434A;
the EU numbering of the Fc portion of SEQ ID No.3 is E216-G446, including the following amino acid substitutions: S228P, F234A, L235A, T307A, E380A, N434A;
the EU numbering of the Fc portion of SEQ ID No.4 is E216-G446, including the following amino acid substitutions: S228P, F234A, L235A, M252Y, T256E, N434A;
2. designing the gene of the designed mutant fusion protein, and carrying out whole-gene synthesis (consignment of Kingsry);
3. constructing the totally synthesized gene into a eukaryotic expression vector (pcDNA3.3, Invitrogen) by adopting a molecular cloning method to obtain an expression construct (Plasmid-X);
4. the expression construct (Plasmid-X) was used to transfect host cells (CHO cells) by electrotransformation and pressure-screening with 800. mu.g/mL G418 (Geneticin);
5. performing Fc mutant fusion protein expression of the mixed clone strains;
6. performing affinity chromatography purification on the Fc mutant fusion Protein by adopting Protein A filler;
7. performing mass spectrum identification on the collected protein, confirming the correctness of the product, and simultaneously performing SDS-PAGE research to determine the purity of the purified protein;
8. the purified fusion protein was diluted to a concentration of 0.1mg/ml with 10mM PBS, and about 0.03-0.04mg of protein per rat was injected in an amount of 0.1mg/kg rat. And sampling at 0h, 2h, 5h, 8h,24h,48h,72h,120h and 168h, detecting by adopting a GLP-1 kit, and finally calculating the half-life period of the drug.
EXAMPLE 1 construction of the vector
Based on the technical route, the following expression vectors (from N end to C end) of the invention are constructed by adopting a molecular cloning method:
GLP-1 analogue (amino acid sequence shown as SEQ ID NO. 6) + peptide linker (amino acid sequence shown as SEQ ID NO. 7) + mutated immunoglobulin Fc part.
The amino acid sequences of the constructed fusion proteins are respectively shown in SEQ ID NOs.1-4 and 8-11.
As a control, vectors encoding (from N-terminus to C-terminus) the following were constructed:
the amino acid sequence of the dolastatin (WT) is shown in SEQ ID NO. 5.
The mutated immunoglobulin Fc part of the present invention is summarized as follows:
TABLE 1
The nucleotide sequences encoding the WT fusion protein (dolabrin) and the IgG4-Fc mutant fusion protein were obtained by chemical synthesis from the encoded amino acid sequence of the trusted smith biotechnology limited (nanjing, china). The obtained synthetic sequence is inserted into the same enzyme cutting sites of a eukaryotic expression vector after double enzyme cutting, and a series of vectors of Plasmid-GLP-1-Fc and mutants are constructed. Then extracting a series of expression vectors which are verified to be correct by adopting an Invitrogen plasmid extraction kit, carrying out linearization by using restriction enzymes, purifying and recovering, and preserving at-20 ℃.
Example 2 vector transfection and expression in cells
After CHO host cells are resuscitated and cultured by CHO culture medium, when the cell density is about 8x105Cells were harvested at individual cells/mL for transfection. Transfected cells about 1X107Cells, approximately 40. mu.g of plasmid, were transfected by the electroporation method (Bio-Rad, Gene pulser Xcell). After the electric shock, the cells were cultured in 20mL of CHO medium. The next day of culture, cells were harvested by centrifugation and resuspended in 20mL CHO medium supplemented with G418(Geneticin ) to a final concentration of 800. mu.g/mL. When the cell density is about 0.6X106When the cell is per mL, the cell density is high,the obtained mixed clone strain was passaged with CHO medium to a cell density of about 0.2X106Individual cells/mL. When the cell survival rate is about 90%, the cell culture solution is collected.
Example 3 purification of fusion proteins from animal cell culture broth
A series of fusion proteins from example 1 were tested at the translation level. A small amount of cell culture solution is enriched by adopting Protein A filler, fusion Protein is collected, the obtained fusion Protein is a homodimer formed by the interaction of disulfide bonds and various non-covalent bonds, mass spectrum detection is carried out, and the mass spectrum detection molecular weight is about 62KD and is consistent with the theoretical molecular weight. The collected fusion Protein was purified using Protein A chromatography column. The collected samples were reduced and then detected by 10% SDS-PAGE electrophoresis, and the electrophoretogram showed a single band of about 36 KD. The purified sample was dialyzed overnight at 4 ℃ against 10mM PBS buffer pH 7.2.
Example 4 pharmacokinetics of fusion proteins in rats
A series of purified fusion proteins were diluted to a concentration of 0.1mg/mL with 10mM PBS. SD rats (0.3-0.4kg) were randomly selected by body weight and administered in a calculated manner by injecting 0.1mg/kg of fusion protein per SD rat, 3 rats per fusion protein were injected subcutaneously.
Prior to administration, approximately 200. mu.l of blood was removed from the jugular vein of each rat, subjected to anticoagulation treatment with EDTA-K2 and a DPP-4 inhibitor, and stored at-20 ℃. Blood is collected for 2h, 5h, 8h,24h,48h,72h,120h and 168h after administration of each animal, and is stored at the temperature of-20 ℃ after anticoagulation treatment.
The drug residues in each blood sample were detected using a GLP-1ELISA detection kit (Millipore) and the pharmacokinetic data were calculated as follows:
TABLE 2
Example 5 in vitro Activity assay of fusion proteins
The purified fusion protein was processed by BCA methodQuantification was performed and then a tripling gradient dilution was performed with Assay buffer (DMEM20ml, FBS 200. mu.l, IBMX 20. mu.l). The cAMP content in cells after the fusion protein stimulates GLP-1R/HEK293 cells is measured by a cAMP detection kit (manufacturer cisbio), namely 5 mul of diluted sample solution is added into a 384 shallow-well plate, 5 mul of cell suspension (the cell density is 100/mul) is added, the mixture is subjected to warm bath in a carbon dioxide incubator for 30min, and then a reaction reagent is added for reaction, and then the fluorescence values of 665nm and 620nm are detected in a multifunctional microplate reader. And drawing a standard curve according to the concentration of the cAMP standard substance and the ratio of the corresponding fluorescence values of the cAMP standard substance, and calculating the amount of cAMP generated by GLP-1R/HEK293 cells stimulated by the test substance under different concentrations. A curve was prepared with the logarithmic value of the concentration of the sample as the abscissa and the nM value of cAMP as the ordinate. The results show that the cAMP content curve in cells after the test sample stimulation is in a typical S-shaped curve, and EC is calculated according to the curve50The value is obtained. The results are shown in the following table and in FIG. 11:
TABLE 3
| Fusion proteins | WT | Na | TENa | MNa |
| EC50Value (nM) | 10.350 | 6.363 | 3.652 | 3.784 |
Example 6 summary and discussion
The crystal structure of the antibody Fc region and its receptor (PDB:1FRT, 4N0U) suggests that the Fc region recognizes FcRn by its flanking amino acids, including: m252, S254, T256, M428, N434, etc. (FIG. 12). The binding force of Fc to its receptor can be changed by site-directed mutation of these flanking amino acids, for example, by mutating M252, S254, T256 to Y252, T254, E256, which introduces mutationNegatively charged residuesE256 andpolar amino acidsAnd T254. There are also groups that introduce mutation of the N434 site to S434, etcPolar amino acidsTo increase the binding of the mutant to the receptor.
The Fc fusion protein designed by the present invention includes an antibody Fc region and a unique drug fusion fragment (GLP-1 or its analog) (fig. 12). Wherein the unique drug fusion fragment contains a flexible region of about 5 nm. In the Fc fusion protein, the E27 site of the GLP-1 protein and the E216 site of the Fc protein (numbered according to the EU numbering system) are both negatively charged; while the K34 site of the GLP-1 protein and the K218 site of the Fc protein (numbered according to the EU numbering system) are both positively charged. And, a continuous polar residue segment, i.e., the peptide linker (G), is intermediate between the GLP-1 protein and the immunoglobulin38GGGSGGGGSGGGGS52). The unique structural characteristic enables the 5nm long drug fusion fragment to have potential interaction with newly introduced charge residues and polar residues on the Fc fragment, and further influences the spatial state of the drug fragment.
The mutation and pharmacokinetic experiments of the present invention also confirm this view (experimental methods and procedures as in the previous examples). In addition to the fusion protein of the present invention, the inventors also introduced a negative charge residue E256 into the Fc region of the fusion protein drug of the present invention to construct four drug candidates YES (amino acid sequence shown in SEQ ID No.8, Fc region containing mutation)
S228P + F234A + L235A + M252Y + T256E + N434S), YTE (amino acid sequence is shown in SEQ ID NO.9, and Fc region contains mutation
S228P + F234A + L235A + M252Y + S254T + T256E), YTELS (amino acid sequence shown in SEQ ID NO.10, Fc region containing mutation
S228P + F234A + L235A + M252Y + S254T + T256E + M428L + N434S) and YE (the amino acid sequence is shown in SEQ ID NO.11, and the Fc region contains a mutation
S228P + F234A + L235A + M252Y + T256E), C thereofmaxValue decrease, t1/2Time advanced and not potentially long acting drug-like (see table 2 for comparison results with the fusion protein of the invention). It can be seen that the introduction of the polar residue S434 in the Fc region results in t1/2The time of the medicine is advanced, and the medicine does not have potential long-acting medicine property. In the process of a pharmaceutical experiment, the weak hydrophobic residue A434 is introduced into an Fc region and can obviously increase t1/2Of which C ismaxThe indexes also show the advantages of the medicine. Thus, the inventors have surprisingly found that: the present inventors have completed the present invention by introducing a weakly hydrophobic residue (e.g., a434) into the Fc fragment of the drug (instead of a polar or charged residue), which can reduce structural self-inhibition between the fused fragment and the Fc fragment, thereby increasing the pharmacokinetic effect.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the description and example should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated by reference in their entirety.
Sequence listing
<110> Guangdong Dongyuang pharmaceutical Co., Ltd
<120> GLP-1 fusion proteins comprising a mutated immunoglobulin Fc portion
<130> IB178011
<150> CN 201610633073.3
<151> 2016-08-03
<160> 11
<170> PatentIn version 3.3
<210> 1
<211> 275
<212> PRT
<213> artificial sequence
<220>
<223> amino acid sequence of fusion protein (Na) comprising Fc mutant 1
<400> 1
His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Gly Gly Gly
20 25 30
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu
35 40 45
Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
50 55 60
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
65 70 75 80
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
85 90 95
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
100 105 110
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
115 120 125
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
130 135 140
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
145 150 155 160
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
165 170 175
Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val
180 185 190
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
195 200 205
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
210 215 220
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr
225 230 235 240
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val
245 250 255
Met His Glu Ala Leu His Ala His Tyr Thr Gln Lys Ser Leu Ser Leu
260 265 270
Ser Leu Gly
275
<210> 2
<211> 275
<212> PRT
<213> artificial sequence
<220>
<223> amino acid sequence of fusion protein (MNa) comprising Fc mutant 2
<400> 2
His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Gly Gly Gly
20 25 30
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu
35 40 45
Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
50 55 60
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
65 70 75 80
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
85 90 95
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
100 105 110
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
115 120 125
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
130 135 140
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
145 150 155 160
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
165 170 175
Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val
180 185 190
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
195 200 205
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
210 215 220
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr
225 230 235 240
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val
245 250 255
Leu His Glu Ala Leu His Ala His Tyr Thr Gln Lys Ser Leu Ser Leu
260 265 270
Ser Leu Gly
275
<210> 3
<211> 275
<212> PRT
<213> artificial sequence
<220>
<223> amino acid sequence of fusion protein (TENA) comprising Fc mutant 3
<400> 3
His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Gly Gly Gly
20 25 30
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu
35 40 45
Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
50 55 60
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
65 70 75 80
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
85 90 95
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
100 105 110
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
115 120 125
Tyr Arg Val Val Ser Val Leu Ala Val Leu His Gln Asp Trp Leu Asn
130 135 140
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
145 150 155 160
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
165 170 175
Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val
180 185 190
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
195 200 205
Ala Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
210 215 220
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr
225 230 235 240
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val
245 250 255
Met His Glu Ala Leu His Ala His Tyr Thr Gln Lys Ser Leu Ser Leu
260 265 270
Ser Leu Gly
275
<210> 4
<211> 275
<212> PRT
<213> artificial sequence
<220>
<223> amino acid sequence of fusion protein (MTNa) comprising Fc mutant 4
<400> 4
His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Gly Gly Gly
20 25 30
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu
35 40 45
Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
50 55 60
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
65 70 75 80
Tyr Ile Ser Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser
85 90 95
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
100 105 110
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
115 120 125
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
130 135 140
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
145 150 155 160
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
165 170 175
Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val
180 185 190
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
195 200 205
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
210 215 220
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr
225 230 235 240
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val
245 250 255
Met His Glu Ala Leu His Ala His Tyr Thr Gln Lys Ser Leu Ser Leu
260 265 270
Ser Leu Gly
275
<210> 5
<211> 275
<212> PRT
<213> artificial sequence
<220>
<223> dolaglutide
<400> 5
His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Gly Gly Gly
20 25 30
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu
35 40 45
Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
50 55 60
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
65 70 75 80
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
85 90 95
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
100 105 110
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
115 120 125
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
130 135 140
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
145 150 155 160
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
165 170 175
Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val
180 185 190
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
195 200 205
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
210 215 220
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr
225 230 235 240
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val
245 250 255
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
260 265 270
Ser Leu Gly
275
<210> 6
<211> 31
<212> PRT
<213> artificial sequence
<220>
<223> representative GLP-1 analogs
<400> 6
His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
1 5 10 15
Gln Ala Ala Leu Glu Phe Ile Ala Trp Leu Val Lys Gly Gly Gly
20 25 30
<210> 7
<211> 16
<212> PRT
<213> artificial sequence
<220>
<223> joint
<400> 7
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala
1 5 10 15
<210> 8
<211> 275
<212> PRT
<213> artificial sequence
<220>
<223> amino acid sequence of YES
<400> 8
His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Gly Gly Gly
20 25 30
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu
35 40 45
Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
50 55 60
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
65 70 75 80
Tyr Ile Ser Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser
85 90 95
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
100 105 110
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
115 120 125
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
130 135 140
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
145 150 155 160
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
165 170 175
Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val
180 185 190
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
195 200 205
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
210 215 220
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr
225 230 235 240
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val
245 250 255
Met His Glu Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser Leu
260 265 270
Ser Leu Gly
275
<210> 9
<211> 275
<212> PRT
<213> artificial sequence
<220>
<223> amino acid sequence of YTE
<400> 9
His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Gly Gly Gly
20 25 30
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu
35 40 45
Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
50 55 60
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
65 70 75 80
Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser
85 90 95
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
100 105 110
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
115 120 125
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
130 135 140
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
145 150 155 160
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
165 170 175
Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val
180 185 190
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
195 200 205
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
210 215 220
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr
225 230 235 240
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val
245 250 255
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
260 265 270
Ser Leu Gly
275
<210> 10
<211> 275
<212> PRT
<213> artificial sequence
<220>
<223> amino acid sequence of YTELS
<400> 10
His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Gly Gly Gly
20 25 30
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu
35 40 45
Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
50 55 60
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
65 70 75 80
Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser
85 90 95
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
100 105 110
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
115 120 125
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
130 135 140
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
145 150 155 160
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
165 170 175
Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val
180 185 190
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
195 200 205
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
210 215 220
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr
225 230 235 240
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val
245 250 255
Leu His Glu Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser Leu
260 265 270
Ser Leu Gly
275
<210> 11
<211> 275
<212> PRT
<213> artificial sequence
<220>
<223> amino acid sequence of YE
<400> 11
His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Gly Gly Gly
20 25 30
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu
35 40 45
Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
50 55 60
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
65 70 75 80
Tyr Ile Ser Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser
85 90 95
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
100 105 110
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
115 120 125
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
130 135 140
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
145 150 155 160
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
165 170 175
Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val
180 185 190
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
195 200 205
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
210 215 220
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr
225 230 235 240
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val
245 250 255
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
260 265 270
Ser Leu Gly
275
Claims (9)
1. A fusion protein comprising or consisting of: GLP-1 or an analog thereof; a peptide linker; and an immunoglobulin Fc portion, wherein the immunoglobulin Fc portion comprises the amino acid substitution N434A, wherein the amino acid sequence of the fusion protein is selected from the group consisting of SEQ ID No.1, SEQ ID No.2, and SEQ ID No. 3.
2. The fusion protein of claim 1, which is present in dimeric form.
3. The fusion protein of claim 2, which is present as a homodimer.
4. A polynucleotide encoding the fusion protein of any one of claims 1-3.
5. A vector comprising the polynucleotide of claim 4.
6. A host cell comprising the vector of claim 5.
7. The host cell of claim 6, wherein the host cell is a CHO cell.
8. A method of producing a fusion protein according to any one of claims 1-3, the method comprising expressing the vector of claim 5 in a host cell.
9. Use of a fusion protein according to any one of claims 1-3 in the manufacture of a medicament for the treatment of diabetes or obesity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610633073 | 2016-08-03 | ||
| CN2016106330733 | 2016-08-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107698684A CN107698684A (en) | 2018-02-16 |
| CN107698684B true CN107698684B (en) | 2021-09-28 |
Family
ID=61072912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710630742.6A Active CN107698684B (en) | 2016-08-03 | 2017-07-28 | GLP-1 fusion proteins comprising a mutated immunoglobulin Fc portion |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN107698684B (en) |
| WO (1) | WO2018024162A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020025306A2 (en) * | 2018-06-18 | 2021-03-09 | Denali Therapeutics Inc. | FUSION PROTEINS UNDERSTANDING PROGRANULIN |
| CN110878127B (en) * | 2018-09-06 | 2022-06-28 | 浙江柏拉阿图医药科技有限公司 | Long-acting recombinant GLP1-Fc-CD47 protein and preparation and application thereof |
| CN110964116A (en) * | 2018-09-26 | 2020-04-07 | 北京辅仁瑞辉生物医药研究院有限公司 | GLP1-Fc fusion proteins and conjugates thereof |
| CA3137907A1 (en) * | 2019-04-24 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof |
| PE20220231A1 (en) * | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | FLT3L-FC FUSION PROTEINS AND METHODS OF USE |
| CN117143242B (en) * | 2023-10-30 | 2024-03-29 | 南京佰抗生物科技有限公司 | Monoclonal antibody composition for resisting Galectin-3 protein and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104327187A (en) * | 2014-10-11 | 2015-02-04 | 上海兴迪金生物技术有限公司 | Recombinant human GLP-1-Fc fusion protein |
| WO2016106302A1 (en) * | 2014-12-23 | 2016-06-30 | Bristol-Myers Squibb Company | Antibodies to tigit |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100166741A1 (en) * | 2006-07-13 | 2010-07-01 | Genentech , Inc. | Altered br-3 binding polypeptides |
| KR20100020516A (en) * | 2007-07-10 | 2010-02-22 | 일라이 릴리 앤드 캄파니 | Glp-1-fc fusion protein formulation |
| WO2009086320A1 (en) * | 2007-12-26 | 2009-07-09 | Xencor, Inc | Fc variants with altered binding to fcrn |
| RS59340B1 (en) * | 2014-11-06 | 2019-10-31 | Hoffmann La Roche | Fc-region variants with modified fcrn-binding and methods of use |
| MY189836A (en) * | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
-
2017
- 2017-07-28 CN CN201710630742.6A patent/CN107698684B/en active Active
- 2017-07-28 WO PCT/CN2017/094916 patent/WO2018024162A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104327187A (en) * | 2014-10-11 | 2015-02-04 | 上海兴迪金生物技术有限公司 | Recombinant human GLP-1-Fc fusion protein |
| WO2016106302A1 (en) * | 2014-12-23 | 2016-06-30 | Bristol-Myers Squibb Company | Antibodies to tigit |
Non-Patent Citations (2)
| Title |
|---|
| Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc;Yang Y等;《PLoS ONE》;20160527;第11卷(第5期);e0156449 * |
| Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice;M Kumar等;《Gene Therapy》;20060831;第14卷;第162-172页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018024162A1 (en) | 2018-02-08 |
| CN107698684A (en) | 2018-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107698684B (en) | GLP-1 fusion proteins comprising a mutated immunoglobulin Fc portion | |
| CN104271588B (en) | The engineered polypeptide of immunogenicity with enhanced acting duration and reduction | |
| JP6509852B2 (en) | Constructs of growth differentiation factor 15 (GDF-15) | |
| JP6519929B2 (en) | GLP-1 analog fusion protein, method for producing the same and use thereof | |
| JP5827218B2 (en) | Peptides for improving in vivo stability, such as physiologically active substances, and physiologically active substances with improved in vivo stability | |
| US11078250B2 (en) | High-activity long-acting hypoglycemic fusion protein as well as preparation method and medical application thereof | |
| CA2565300A1 (en) | Fgf-21 fusion proteins | |
| CN106986940A (en) | Engineered polypeptide with enhanced acting duration | |
| US20210253662A1 (en) | Long-Acting Recombinant GLP1-Fc-CD47 Protein and Preparation and Use Thereof | |
| CN108220315A (en) | The preparation method and fusion protein of a kind of small molecular protein or polypeptide | |
| CN102690352A (en) | Fusion protein containing GLP-1, and pharmaceutical compositions and applications thereof | |
| CN113105561B (en) | Preparation method and application of double-target fusion protein | |
| JP6612360B2 (en) | Fusion protein complex and fusion protein having medicinal action | |
| CN113968911B (en) | insulin-Fc fusion protein and application thereof | |
| CN110172103B (en) | GLP-1 analogue-Fc fusion protein, and preparation method and application thereof | |
| CN106008717B (en) | Long-acting recombinant GLP-1 fusion protein and preparation method and application thereof | |
| US10017555B2 (en) | Long-acting blood sugar decreasing fusion protein | |
| CN111217915B (en) | GLP-1 analogue Fc fusion polypeptide and application thereof | |
| CN111269312B (en) | Heterologous fusion protein | |
| CN111269321B (en) | GLP-1 analogue fusion protein | |
| CN106146667B (en) | Exendin-4 fusion protein and preparation method and application thereof | |
| WO2023280133A1 (en) | Fusion protein and application thereof | |
| CN114106194A (en) | Fusion protein for treating diabetes and/or obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523808 No.1 Gongye North Road, Songshan Hubei Industrial Park, Dongguan City, Guangdong Province Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
| CP03 | Change of name, title or address |